![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer Pledges Warranty for NSCLC Drug Should It Fail to Provide Benefit
Pfizer Pledges Warranty for NSCLC Drug Should It Fail to Provide Benefit
Pfizer has quietly launched what it’s calling the Pfizer Pledge, a pilot program that attaches an insurance-backed warranty to the performance of the company’s 10-year-old lung cancer drug Xalkori, promising money back.
The pledge: If Xalkori (crizotinib) doesn’t work in the first three months of treatment in U. S. patients with metastatic nonsmall-cell lung cancer (NSCLC), Pfizer will refund the cost of the drug to whomever paid for it — whether a cash-paying patient, an insurance company or Medicare Part D.
Specifically, said Pfizer in a statement to FDAnews, the program is available to patients prescribed Xalkori for metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. It’s also available to pediatric patients who are one year old or older and young adults with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) that is ALK-positive.
A 30-day supply of Xalkori is $19,144, according to Pfizer’s webpage on the program. Each patient in the program can get a maximum of $57,432 back if they take the drug for three months and can show that they experienced no benefit.
Upcoming Events
-
21Oct